内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetes Care：GLP-1受体激动剂可以作为青少年的成年发病型糖尿病(MODY)3型的替代治疗

2014-06-19 MedSci MedSci原创

GLP-1糖尿病MODY
关注

HNF1A糖尿病[青少年的成年发病型糖尿病(MODY)3型]患者通常使用磺脲类药物治疗，面临低血糖频发风险。第2项研究是一项双盲、随机、交叉试验，探索GLP-1受体激动剂能否作为有效的替代选择。研究纳入的16例HNF1A糖尿病患者随机接受格列美脲(n=8)或利拉鲁肽 (n=8)治疗6周。 结果表明，两组患者的空腹血糖(FPG，主要疗效终点)和餐后血糖水平均较基线显著下降，胰岛素和C肽反应提

HNF1A糖尿病[青少年的成年发病型糖尿病(MODY)3型]患者通常使用磺脲类药物治疗，面临低血糖频发风险。第2项研究是一项双盲、随机、交叉试验，探索GLP-1受体激动剂能否作为有效的替代选择。研究纳入的16例HNF1A糖尿病患者随机接受格列美脲(n=8)或利拉鲁肽 (n=8)治疗6周。

结果表明，两组患者的空腹血糖(FPG，主要疗效终点)和餐后血糖水平均较基线显著下降，胰岛素和C肽反应提高，组间均无显著性差异;利 拉鲁肽组低血糖事件显著更少(18次对1次)。作者就此指出GLP-1受体激动剂有望在MODY患者、特别是治疗相关低血糖事件频发患者的治疗中占有一席。

原始出处：

Ostoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, Knop FK, Vilsbøll T.Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial.Diabetes Care. 2014 Jun 14. pii: DC_133007

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2015-04-11 x35042875

    国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2014-08-28 wfang555

    #替代治疗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2015-02-22 木头人513

    #Diabetes#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2014-11-21 智智灵药

    #BET#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2015-04-05 ms9608593228839890

    #DIA#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2015-04-07 fusion

    #MODY#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2014-06-21 Eleven11

    #GLP-1受体激动剂#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2014-06-21 yibei

    #GLP-1#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2014-06-21 medscijoin

    #激动剂#

    0

相关资讯

BMJ：GLP-1类药物的安全性受到质疑

新型的糖尿病药物，像GLP-1类药物，被称为“糖尿病治疗的宠儿”–带给制药工业数十亿的收入。但是，这类药物是否与癌症风险增加有关，以及关于这些新治疗方案，我们是否完全了解？ 英国医学杂志（BMJ）和第四频道发起了一项调查研究，发现在行业研究中提示这类药物具有潜在危害的证据没有被公开。一些独立研究的结果对药品生产厂家的结论提出质疑。目前一些医学专家和患者团体要求制药公司报告的研究数据更加透明，并参

Sanofi推迟GLP-1受体激动剂lixisenatide在FDA的申请

    2013年9月12日，Sanofi称在与FDA交流后，该公司决定撤回GLP-1受体激动剂lixisenatide的申请，等待该药正在进行的III期ELIXA研究所有数据出来。这样新申请将推迟到2015年。这个药物已经在欧洲以Lyxumia的商品名出售。    前期的GetGoal系列研究结果显示，每日一次（早上应用，或晚上应用

朱大龙：GLP-1降糖药物的临床应用共识

　　肠促胰素引起的胰岛素分泌能力约占全部胰岛素分泌量的50~70%，而且这一作用具有葡萄糖浓度依赖的特点，故在调节血糖的同时，引起低血糖的风险很低。此外，GLP-1可抑制胰腺α细胞分泌胰高糖素，并有减轻体重、改善β细胞功能和在动物模型中增加β细胞量的作用，可对2型糖尿病患者的代谢异常进行多方面的调控。EMA在2013年7月25日发表GLP-1相关药物的评估报告中，目前没有证据支持GLP-1增加胰腺

胰高血糖素样肽-1（GLP-1）保护胰岛β细胞相关分子机制的研究进展

  胰高血糖素样肽-1(Glucagon-like peptide-1,GLP-1)是肠道L细胞分泌的一种重要的肠促胰岛素.大量研究表明,除刺激胰岛素分泌外,GLP-1可通过促进胰岛β细胞增殖,抑 制β细胞凋亡而增加胰岛β细胞量,本文就其相关分子信号转导机制进行综述. 胰高血糖素样肽-1保护胰岛β细胞相关分子机制的研究进展.pdf

Neuropharmacology：GLP-1受体可能是慢性疼痛的关键靶点

上海交通大学药学院王永祥带领的科研团队找到慢性疼痛克星。5月7日，研究团队对外首次发布了发现脊髓GLP-1受体可在慢性疼痛中产生有效镇痛作用的消息，新发现的镇痛新靶点，能对肿瘤癌症、糖尿病等疼痛抑制率达到60%-90%。   慢性疼痛家族包括头疼、牙疼，还有炎症痛、肿瘤癌症痛、神经源性痛、糖尿病疼痛和腰背痛等。尤其是糖尿病患者中25%存在神经性疼痛；肿瘤癌症患者，常常也伴有长期的、不

CDS 2013：郭立新教授谈新型糖尿病药物GLP-1新近进展

　　  郭立新教授 GLP-1对不同类型糖尿病患者治疗策略的影响 胰高血糖素样肽-1(GLP-1)具有葡萄糖浓度依赖型降糖作用，改善糖尿病患者的代谢异常，其机制已经基本明确。新近颁布的指南和共识对以肠促胰激素为基础的治疗模式大都给予了良好的评价。以往的研究多是关注其对于2型糖尿病(T2DM)患者的影响，最近的研究显示，对于1型糖尿病(T1DM)患者，GLP-1也显示出良